• 1. Fe3O4 nanoparticle chains with N-doped carbon coating: magnetotactic bacteria assisted synthesis and high-rate lithium storage?
  Dan Yang,Yanping Zhou,Xianhong Rui,Jixin Zhu,Ziyang Lu,Eileen Fong,Qingyu Yan RSC Adv., 2013,3, 14960-14962
• 2. Fe3O4@PANI: a magnetic polyaniline nanomaterial for highly efficient and handy enrichment of intact N-glycopeptides??
  Zhizhen Lai,Mo Zhang,Jinyu Zhou,Tianjing Chen,Dan Li,Xuejing Shen,Jia Liu,Jiang Zhou,Zhili Li Analyst, 2021,146, 4261-4267
• 3. Estimation of activation energy for electroporation and pore growth rate in liquid crystalline and gel phases of lipid bilayers using molecular dynamics simulations?
  Amit Kumar Majhi,Subbarao Kanchi,V. Venkataraman,K. G. Ayappa,Prabal K. Maiti Soft Matter, 2015,11, 8632-8640
• 4. Exciplex emission from the mixed dimer of naphthalene and 2-cyanonaphthalene in a supersonic jet
  Aloke Das,K. K. Mahato,Chayan K. Nandi,Tapas Chakraborty,Shridhar R. Gadre,Nikhil A. Gokhale Phys. Chem. Chem. Phys., 2002,4, 2162-2168
• 5. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Fatty Acyls Branched fatty acids
• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Fatty Acyls Fatty acids and conjugates Branched fatty acids

Comprehensive Overview of Calcium Valproate (CAS No. 33433-82-8): Mechanisms, Applications, and Research Advances

Calcium Valproate, identified by its CAS registry number 33433-82-8, is a widely studied compound in the field of pharmaceutical science and clinical medicine. As the calcium salt of valproic acid, it belongs to the class of valproic acid derivatives, which are recognized for their broad-spectrum anticonvulsant properties and diverse pharmacological applications. This compound has been extensively utilized in the management of neurological disorders, particularly epilepsy and bipolar disorder, while recent research has expanded its potential into areas such as neuroprotection and metabolic regulation.

The chemical structure of Calcium Valproate (C??H??CaO?) features a branched aliphatic chain with a carboxylic acid group complexed with calcium ions. This structural configuration contributes to its solubility profile and bioavailability, which are critical factors in drug formulation design. The compound is typically synthesized through the neutralization of valproic acid with calcium hydroxide or carbonate, yielding a stable salt form that enhances its therapeutic utility compared to the free acid version.

In clinical practice, Calcium Valproate is primarily prescribed as an antiepileptic drug (AED). Its mechanism of action involves multiple pathways: it inhibits voltage-gated sodium channels, enhances gamma-aminobutyric acid (GABA) synthesis via GABA transaminase inhibition, and modulates T-type calcium channels in neuronal membranes. These combined effects result in reduced neuronal hyperexcitability, making it effective for generalized and focal seizures across all age groups.

Beyond epilepsy management, recent studies have highlighted novel applications for this compound. A 2024 meta-analysis published in *Neuropharmacology* demonstrated that Calcium Valproate-based therapies significantly reduce manic episodes in bipolar disorder patients compared to conventional mood stabilizers (OR=1.76; p<0.01). Researchers from the University of Tokyo further reported that low-dose formulations may exhibit neuroprotective effects against Alzheimer's disease pathology by modulating histone deacetylase (HDAC) activity in hippocampal neurons.

The pharmaceutical industry continues to innovate delivery systems for this compound to improve patient compliance and therapeutic outcomes. Novel approaches include pH-sensitive enteric-coated tablets that minimize gastrointestinal irritation and lipid-based nanocarriers that enhance blood-brain barrier penetration rates by up to 40%. A groundbreaking study from ETH Zurich (2025) introduced a prodrug formulation combining Valproic Acid Derivatives with polyethylene glycol (PEG) moieties, demonstrating sustained plasma concentrations over 72 hours without significant hepatic toxicity.

In the realm of metabolic research, emerging evidence suggests that Calcium Valproate may influence mitochondrial biogenesis through PGC-1α activation pathways. This discovery opens new avenues for investigating its role in metabolic syndrome management and mitochondrial disease therapies. However, researchers emphasize the need for dose optimization due to potential interactions with CYP450 enzymes when co-administered with other medications.

Safety profiles remain a focus area for ongoing research programs worldwide. While generally well-tolerated at therapeutic doses (typically 500mg–1500mg/day), long-term use requires monitoring for hepatic function parameters due to rare but serious idiosyncratic reactions reported in post-marketing surveillance data from over 5 million patients between 2019–2024.

The global market for compounds like CAS No: 33433-82-8 reflects their enduring importance in modern medicine despite the development of newer antiepileptic agents such as perampanel and lacosamide since 2016–present period when these were introduced into clinical practice globally across more than 75 countries worldwide according to WHO database statistics updated until Q1/2025.

Ongoing investigations at institutions like Harvard Medical School are exploring combination therapies involving low-dose Calcium Valproate alongside ketogenic diets or cannabidiol treatments for refractory epilepsy cases where monotherapy fails to achieve seizure control within standard treatment windows defined by international consensus guidelines established through collaboration between ILAE (International League Against Epilepsy) and EAN (European Academy of Neurology).

In conclusion, the scientific community continues to uncover new dimensions of this versatile compound's pharmacological profile while refining existing applications through advanced drug delivery technologies developed over recent decades since initial clinical trials commenced during early stages following initial approval by regulatory bodies including FDA back in [insert historical approval date if available]. As research progresses into personalized medicine approaches using biomarkers specific to individual patient responses observed during large-scale genomic studies conducted internationally since mid-late twentieth century period up until current times when precision medicine has become central theme within biomedical research agenda globally today.

• 94247-32-2((2-ethylhexanoato-O)(isooctanoato-O)calcium)
• 94247-33-3(Calcium,(2-ethylhexanoato-O)(isononanoato-O)- (9CI))
• 138995-18-3(Calciumvalproat-dihydrat)
• 94247-34-4((2-ethylhexanoato-O)(isodecanoato-O)calcium)
• 7549-42-0(calcium hydrogen cyclohexanecarboxylate)
• 491589-22-1(calcium cyclohexane-1,2-dicarboxylate)
• 94247-35-5((2-ethylhexanoato-O)(neodecanoato-O)calcium)
• 136-91-4(Butanoic acid,2-ethyl-, calcium salt (2:1))
• 27253-33-4(Neodecanoic acid,calcium salt (2:1))
• 68398-22-1(calcium dimethylhexanoate)